Maagaard Mathias, Andersen Jakob Hessel, Jaeger Pia, Mathiesen Ole
Anaesthesiology, Zealand University Hospital, Koge, Denmark
Anaesthesiology, Zealand University Hospital, Koge, Denmark.
Reg Anesth Pain Med. 2025 Apr 10;50(4):311-320. doi: 10.1136/rapm-2023-105098.
BACKGROUND/IMPORTANCE: The effects of combining dexamethasone and dexmedetomidine on block duration are unclear.
To investigate the effects of combining dexamethasone and dexmedetomidine on block duration.
Systematic review of randomized controlled trials (RCTs) from Medline, Embase, CENTRAL, CINAHL, the Web of Science, and BIOSIS until June 8, 2023. RCTs with adults undergoing surgery with a peripheral nerve block randomized to combined dexamethasone and dexmedetomidine versus placebo or other adjuncts were eligible. Primary outcome was duration of analgesia. We performed meta-analysis, trial sequential analysis, risk of bias-2, and Grading Recommendations Assessment, Development, and Evaluation assessment.
We included 9 RCTs with 14 eligible comparisons. The combination of dexamethasone and dexmedetomidine was compared with placebo in three RCTs (173 participants), dexamethasone in seven (569 participants), and dexmedetomidine in four (281 participants). The duration of analgesia was likely increased with the combination versus placebo (mean difference 460 min, 95% CI 249 to 671) and versus dexmedetomidine (mean difference 388 min, 95% CI 211 to 565). The duration was likely similar with the combination versus dexamethasone (mean difference 50 min, 95% CI -140 to 239). The certainty of the evidence was moderate because most trials were at high risk of bias.
Combined dexamethasone and dexmedetomidine likely increased the duration of analgesia when compared with placebo and dexmedetomidine. The combination likely provided a similar duration of analgesia as dexamethasone. Based on this systematic review, it seems reasonable to use dexamethasone as the sole adjunct if the goal is to increase the duration of analgesia.
背景/重要性:地塞米松与右美托咪定联合使用对阻滞持续时间的影响尚不清楚。
探讨地塞米松与右美托咪定联合使用对阻滞持续时间的影响。
对截至2023年6月8日来自Medline、Embase、CENTRAL、CINAHL、科学网和BIOSIS的随机对照试验(RCT)进行系统综述。纳入接受外周神经阻滞手术的成年患者,随机分为地塞米松与右美托咪定联合组、安慰剂组或其他辅助药物组的RCT符合要求。主要结局是镇痛持续时间。我们进行了荟萃分析、试验序贯分析、偏倚风险-2评估以及推荐分级的评估、制定与评价评估。
我们纳入了9项RCT,有14项符合条件的比较。在3项RCT(173名参与者)中,地塞米松与右美托咪定联合组与安慰剂组进行了比较;在7项RCT(569名参与者)中,与地塞米松组进行了比较;在4项RCT(281名参与者)中,与右美托咪定组进行了比较。与安慰剂相比,联合使用地塞米松与右美托咪定可能会增加镇痛持续时间(平均差值460分钟;95%置信区间249至671),与右美托咪定相比也是如此(平均差值388分钟;95%置信区间211至565)。与地塞米松相比,联合使用组的镇痛持续时间可能相似(平均差值50分钟;95%置信区间-140至239)。证据的确定性为中等,因为大多数试验存在高偏倚风险。
与安慰剂和右美托咪定相比,地塞米松与右美托咪定联合使用可能会增加镇痛持续时间。联合使用组的镇痛持续时间可能与地塞米松相似。基于这项系统综述,如果目标是增加镇痛持续时间,仅使用地塞米松作为辅助药物似乎是合理的。